Swiss drugmaker Novartis (NOVN.S) is in the lead to acquire Cytokinetics (CYTK.O) for a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,